A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor

Archives of Neurology

Volumn 56, Issue 4, 1999, Pages 475-480

  Gironell, Alexandre ^a,b   Kuliscvsky, Jaime ^a,e   Barbanoj, Manel ^c   Lopcz Villegas, Dolores ^c,d   Heniández, Gonzalo ^a,e   Pascual Sedano, Berta ^b,d  

^a Fundació de G S de l'Hospital de la Santa Creu Sant Pau   (Spain)

^b Research Institute   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d Research and Development Department   (Spain)

^e Hospital de la Santa Crcu I Sain Pau   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN; PROPRANOLOL;

ABDOMINAL CRAMP; ACCELEROMETER; ADULT; AGED; ANTICONVULSANT ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DAILY LIFE ACTIVITY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ESSENTIAL TREMOR; FEMALE; HUMAN; MALE; OUTCOMES RESEARCH; PARESTHESIA; PATIENT SELECTION; PERFORMANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SELF EVALUATION; SOMNOLENCE; TREATMENT OUTCOME;

EID: 0032893712     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.56.4.475     Document Type: Article

References (34)

1. Findley LJ, Koller WC. Essential tremor: a review. Neurology. 1987;37:1194-1197.
2. Koller W, Biary N, Cone S. Disability in essential tremor: effect of treatment. Neurology. 1986:36:1001-1004.
3. Findley LJ. The pharmacology of essential tremor. In: Marsden CO, Fahn S, eds. Movement Disorders. Vol 2. London, England: Butterworths; 1987:438-458.
4. Busenbark KL, Nash J, Nash S, Hubble JP, Koller WC. Is essential tremor benign? Neurology. 1991:41:1982-1983.
5. Hubble JP, Busenbark KL, Koller WC. Essential tremor. Clin Neuropharmacol. 1989:12:453-482.
6. Winkler GF, Young RR. Efficacy of chronic propranolol therapy in action tremors of the familial, senile or essential varieties. N Engl J Med. 1974:290:984-988.
7. O'Brien MD, Upton AR, Toseland PA. Benign familial tremor treated with primidone. BMJ. 1981:282:178-180.
8. Chakrabarti A, Pearce JMS. Essential tremor: response to drimidone [letter]. J Neurol Neurosurg Psychiatry. 1981 ;44:650.
9. Findley LJ, Cleeves L, Calzetti S. Primidone in essential tremor of the hands and head: double-blind controlled clinical study. J Neurol Neurosurg Psychiatry. 1985; 48:911-915.
10. Calzetti S, Findley LJ, Perucca E, Richens A. The response of essential tremor to propranolol: evaluation of clinical variables governing its efficacy on prolonged administration. J Neurol Neurosurg Psychiatry. 1983:46:393-398.
11. Koller WC, Royse VL. Efficacy of primidone in essential tremor. Neurology. 1986; 36:121-124.
12. Gorman WP, Cooper R, Pocock P, Campbell MJ. A comparison of primidone, propranolol, and placebo in essential tremor, using quantitative analysis. J Neurol Neurosurg Psychiatry. 1986:49:64-68.
13. Burrows GT, King RB. Gabapentin in essential tremor. Neurology. 1995:45 (suppl 4):A187-A188.
14. Pahwa R, Lyons K, Hubble JP, et al. Double-blind placebo-controlled study of gabapentin in essential tremor. Mov Disord. 1998:13:465-467.
15. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomédical research involving human subjects. JAMA. 1997:277:925-926.
16. Jones B, Kenward MG. Design and Analysis of Cross-Over Trials. London, England: Chapman & Hail; 1989. Monographs on Statistics and Applied Probability.
17. Fahn S, Tolosa E, Marin C. Clinical rating scale for tremor. In: Jankovic J, Tolosa E, eds. Parkinson's Disease and Movement Disorders. Baltimore, Md: Urban & Schwarzenberg; 1988:225-234.
18. Kulisevsky J, Avila A, Barbanoj M, Antonijoan R, Torres J, Arcelus R. Levodopa does not aggravate postural tremor in Parkinson's disease. Clin Neuropharmacol. 1995:18:435-442.
19. Bain PG, Findley LJ, Atchison P, et al. Assessing tremor severity. J Neurol Neurosurg Psychiatry. 1993:56:868-873.
20. Senn S. Crossover Trials in Clinical Research. Chichester, England: John Wiley & Sons Ltd; 1993:117-142.
21. Altman DG. Practical Statistics for Medical Research. London, England: Chapman & Hall; 1991.
22. Elble RJ. Physiologic and essential tremor. Neurology. 1986:36:225-231.
23. Sabra AF, Hallet M. Action tremor with alternating activity in antagonist muscles. Neurology. 1984;34:151-156.
24. Chadwick D. Gabapentin. Lancet. 1994:343:89-91.
25. Richens A. Clinical pharmacokinetics of gabapentin. In: Chadwick D, ed. New Trends in Epilepsy Management: The Role of Gabapentin. London, England: Royal Society of Medicine Services; 1993:41-46.
26. Handforth A, Treiman DM. Efficacy and tolerance of long-term, high-dose gabapentin: additional observations. Epilepsia. 1994;35:1032-1037.
27. Bergey GK, Morris HH, Rosenfeid W, etal. Gabapentin monotlierapy, I: an 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. Neurology. 1997:49:739-745.
28. Taylor CP. Gabapentin: mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs. New York, NY: Raven Press; 1995:829-841.
29. Petroff OA, Rothman DL, Behar KL, Lamoureux D, Mattson RH. The effect of gabapentin on brain y-aminobutyric acid in patients with epilepsy. Ann Neurol. 1996; 39:95-99.
30. Ziemann U, Lönnecker B, Steinhoff BJ, Paulus W. Effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study. Ann Neurol. 1996:40:367-378.
31. Elble RJ. Central mechanisms of tremor. J Clin Neurophysiol. 1996;13:133-144.
32. Lamarre Y. Tremorgenic mechanisms in primates. Adv Neurol. 1975:10:23-34.
33. Hendry SHC, Schwark HD, Jones EG, Yan J. Numbers and proportions of GABA immunoreactive neurons in different areas of monkey cerebral cortex. J NeuroscJ. 1987:7:1503-1519.
34. 11C-flumazenil and PET. Eur J Heurol. 1996;3(suppl 5):173.